Celltrion to select lead antibody candidates to fight COVID-19
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
List view / Grid view
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced and the various treatment strategies that are currently being adopted.
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Cell line development typically includes the screening of thousands of clones to identify the few that are stable, grow as expected and produce high yields of the bioproduct.
The articles in this antibodies In-Depth Focus assess the methods used to develop antibody therapeutics and the evolution of this area of medicine to identify drug targets.
Novel therapy uses antibodies cloned from patients who have recovered from an infection caused by the fungus Candida…
9 November 2018 | By Beckman Coulter
In this webinar you learn about a high throughput screening approach for mining of antibody repertoires in the context of biologics drug discovery.
Investigational therapeutic candidate made with four antibodies tethered together shows promise against influenza A and B...